Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Only the general indication (spasticity) and broad MOA elements (central alpha-2-adrenergic agonist; central nervous system effect) are supported. Multiple mechanistic details, spasticity definition/etiologies, and dosage-form/brand-name assertions are unsupported or overstated versus the provided label text, lowering overall alignment.
Category Scores
Accurate Statements
Tizanidine is used to treat spasticity.
Supported by 1 INDICATIONS AND USAGE (Ontralfy indicated for treatment of spasticity in adults).
Tizanidine works by acting as an alpha-2 adrenergic agonist.
Supported by 11 DESCRIPTION and 12.1 Mechanism of Action.
Tizanidine acts on the central nervous system.
Supported by 11 DESCRIPTION and 12.1 Mechanism of Action.
Unsupported Statements
Tizanidine is also known by its brand name, Zanaflex.
No support provided in the available label text.
Spasticity is increased muscle tone that can occur with multiple sclerosis, spinal cord injury, or stroke.
Not supported in the provided label sections.
Tizanidine helps to relax muscles.
Only partially supported by the supplied mechanism wording; phrased as a clear therapeutic effect not explicitly stated in the provided label text.
Tizanidine specifically acts at alpha-2 adrenergic receptors in the spinal cord.
Label suggests greatest effects on polysynaptic pathways and reduction in spinal motor neuron facilitation, but the explicit statement of receptor location in the spinal cord is only partially supported by the provided text.
By stimulating alpha-2 adrenergic receptors, tizanidine inhibits the release of excitatory amino acids.
Not supported by the provided label text.
Inhibition of excitatory amino acids leads to a reduction in muscle tone and spasticity.
Not supported by the provided label text.
Tizanidine is available as an oral capsule.
Not supported for the available label product; label provided discusses Ontralfy oral solution and comparisons to tizanidine tablets/capsules without stating availability for the drug being described.
Tizanidine is available as an oral tablet.
Not supported for the available label product; label provided discusses Ontralfy oral solution and comparisons to tizanidine tablets/capsules without stating availability for the drug being described.
Contradictions
Important Omissions
No claim set included core FDA-label safety elements (e.g., contraindications, boxed warnings, detailed warnings/precautions, dosing regimen). While not directly required to answer the specific extracted claims, these omissions prevent assessment of safety alignment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/overstated mechanistic details and incorrect/unsupported dosage-form/brand-name assertions could mislead interpretation of the label. The only clearly supported efficacy/indication statement is spasticity; no safety/contraindication alignment can be assessed from the provided claim set.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Not Aligned
Primary Issue
Multiple claims are unsupported or only partially supported by the provided label text, including brand name, spasticity definition/etiologies, expanded MOA details, and dosage-form availability statements.
Suggested Improvement
Restrict claims to what is explicitly supported in the provided label sections (indication for spasticity in adults; central alpha-2-adrenergic agonist; general mechanism language). Remove or rephrase mechanistic steps and any product dosage-form/brand-name availability not supported by the provided label text.